. Author manuscript; available in PMC: 2025 Jul 20.

Published in final edited form as: Lancet Glob Health. 2024 Nov 14;13(1):e134–e145. doi: 10.1016/S2214-109X(24)00373-5

Table 2. Trial outcomes.

	Intervention	Control	Cluster-level geometric mean prevalence (GSD)		Adjusted risk ratio^* (95% CI)	p value	Between-cluster coefficient of variation
	Intervention	Control	Intervention (n=8)	Control (n=8)	Adjusted risk ratio^* (95% CI)	p value	Between-cluster coefficient of variation
Primary outcome
C trachomatis, N gonorrhoeae, and T vaginalis^†	538/2756	569/2845	19·07% (1·20)	19·95% (1·10)	0·93 (0·78–1·10)	0·35	0·15
Secondary outcomes
C trachomatis ^‡	358/2756	382/2922	12·86% (1·14)	12·94% (1·15)	0·97 (0·84–1·11)	0·60	0·13
N gonorrhoeae ^‡	52/2756	85/2829	1·65% (1·77)	2·87% (1·43)	0·57 (0·34–0·96)	0·036	0·50
T vaginalis ^‡	213/2756	189/2922	7·06% (1·48)	6·20% (1·38)	1·09 (0·74–1·60)	0·66	0·38
Exploratory outcome
C trachomatis and N gonorrhoeae^§	393/2756	439/2839	14·06% (1·17)	15·40% (1·15)	0·89 (0·75–1·05)	0·15	0·14

C trachomatis=Chlamydia trachomatis. GSD=geometric standard deviation. N gonorrhoeae=Neisseria gonorrhoeae. T vaginalis=Trichomonas vaginalis.

Adjusted for sex and age in years.

^†

Population-level prevalence of any (one or more) of C trachomatis, N gonorrhoeae, and T vaginalis.

^‡

Population prevalence of single infection.

^§

Population-level prevalence of one or both of C trachomatis and N gonorrhoeae.